The Why, What and When of spinout companies
Event description
If you are new to the world of spinout companies or new venture creation, then this is just the introduction you need to start the journey. Whether you are in a Technology Transfer Office, Knowledge Exchange Office or you’re in an incubator, this course will cover the key steps you’ll need to take and the main issues you are likely to face. Hear from course directors who have spun out companies in a range of institutions; learn more about social ventures and understand what early-stage investors are looking for.
Training outcomes
Delegates on this course should be advised that this is an Introduction to New Ventures, and if you are already involved in spin-outs and new ventures on a regular basis our New Venture Creation; Advanced (NVC2) might be at a more appropriate level. Find out more.
You will understand why you should consider starting a company, how to manage pressure to form one, and what success may look like.
You will learn what you need to look for in an opportunity and what business models you could consider.
You will learn the steps towards creating a company, what types of companies you could form, and the key factors you should plan to have in place.
You will be able to identify likely pitfalls and explore their mitigation.
You will also hear about the journey from the perspective of different types of ventures drawn from scientific and non-scientific disciplines.
Learner Journey
Route 1
New Venture Creation; An Introduction. A one day course, stand-alone for those new to venture creation and spin-outs.
Route 2
New Venture Creation; An Introduction and New Venture Creation; Advanced. A three day programme delivered consecutively, giving delegates the foundations followed by a deeper dive in the practicalities of new venture planning, and management.
Route 3
New Venture Creation; Advanced. A two day course for those how already know the basics and have a good understanding of the context of new venture creation. The Advanced course will offer delegated practical advice and processes for scoping projects, working with investors and managing common pitfalls.
2024 Dates
Venue - Woodland Grange, Old Milverton Ln, Leamington Spa CV32 6RN
- Registration Evening - Monday 14 October 2024
- Day 1 - Tuesday 15 October 2024
Costs do not include accommodation and travel. PraxisAuril cannot make bookings on behalf of delegates. You will receive further information regarding booking your accommodation in the confirmation email.
Event fee: Non-Members £895 Members £625
2025 Dates
October 2025 (cannot be attended remotely)
Venue: TBC
Costs do not include accommodation and travel. PraxisAuril cannot make bookings on behalf of delegates. Once you have made your booking, you will receive your accommodation reference in your confirmation email.
Event fee: Non-Members £TBC Members £TBC
If you are interested in attending this course, please let us know and join our Interest Group by clicking on the button below.
Who should attend?
- Relevant job titles: Relevant to anyone working in KE
- Relevant sectors/organisations: Higher education and public sector research environment, incubators or accelerators who support new venture creation
- Experience needed: KE field experience and/or a little practical experience in company formation. Delegates might have significant experience in TT/KT or KE, but little practical experience of new venture formation and may be looking to take the first steps in assessing and supporting new venture opportunities.
- Supporting courses: None required
- Other: The course is an ideal primer for New Venture Creation 2 which deals with these issues in greater detail and gives additional insight in how to form a high-growth company with VC finance
- This course will contain; group work, network evenings, and interactive activities.
Course Directors
Jacqueline Barnett, BScEng, MScEng, MBA, RTTP
Jaci is the Head of Consulting Services at Oxford University Innovation, the wholly owned technology transfer company of the University of Oxford. She has over 20 years’ experience in research commercialisation and technology transfer and has, during that time, managed technology transfer offices, managed contract research and consultancy functions, led a regional technology transfer office, launched a regional innovation forum, established an incubator, and had both non-executive and executive roles on the boards of start-up and spinout companies.
Until August 2017, Jaci was Head of Research Commercialisation and Investment at the University of Bristol and, prior to that, was Director of the Innovation Office at Nelson Mandela University in South Africa for over ten years. She has an undergraduate and master’s degree (by research) in Chemical Engineering from the University of Natal, Durban, South Africa, and an MBA (cum laude) from the University of Pretoria. After starting her career in industry, she moved to a contract research organisation and, in 2005, entered the higher education sector as Chief Operations Officer at Wits Enterprise, the commercialisation company of the University of the Witwatersrand, Johannesburg. Jaci was previously President of the Southern African Research and Innovation Management Association (SARIMA), was on the Council of the Alliance of Technology Transfer Professionals (ATTP), and was Chair of ATTP’s Course Review Committee from 2013 to 2020. She is a Registered Technology Transfer Professional and is currently a PhD candidate at the University of Bristol, exploring metrics for impact of spinout companies.
Andrew Wilson, Head of Commercialisation at the University of Bristol
Andrew is Head of Commercialisation at the University of Bristol where he manages the team responsible for licensing and new company creation. He also manages his existing portfolio of projects in Health Sciences where he facilitates the translation and commercialisation of a broad range of technologies and healthcare interventions.
Andrew is a Registered Technology Transfer Professional and has 20 years experience in Technology Transfer roles, first at the University of West of England and then at the University of Bristol. He is an experienced non-executive director who has been on the board of a number of therapeutic, medical device and public health focused spin-out companies.
Andrew has led and supported a large number of spin-out transactions, including Purespring Therapeutics (a Syncona-backed renal gene therapy company) and IRISi Ltd (an award-winning social enterprise established to promote and improve the healthcare response to domestic violence and abuse).